376 related articles for article (PubMed ID: 28578484)
1. Valbenazine: First Global Approval.
Kim ES
Drugs; 2017 Jul; 77(10):1123-1129. PubMed ID: 28578484
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.
Niemann N; Jankovic J
Drugs; 2018 Apr; 78(5):525-541. PubMed ID: 29484607
[TBL] [Abstract][Full Text] [Related]
3. Valbenazine as the first and only approved treatment for adults with tardive dyskinesia.
Sarva H; Henchcliffe C
Expert Rev Clin Pharmacol; 2018 Mar; 11(3):209-217. PubMed ID: 29338466
[TBL] [Abstract][Full Text] [Related]
4. Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other?
Stahl SM
CNS Spectr; 2018 Aug; 23(4):239-247. PubMed ID: 30160230
[TBL] [Abstract][Full Text] [Related]
5. Efficient Trial Design - FDA Approval of Valbenazine for Tardive Dyskinesia.
Davis MC; Miller BJ; Kalsi JK; Birkner T; Mathis MV
N Engl J Med; 2017 Jun; 376(26):2503-2506. PubMed ID: 28489481
[No Abstract] [Full Text] [Related]
6. Valbenazine for the treatment of tardive dyskinesia.
Barquero N
Drugs Today (Barc); 2016 Dec; 52(12):665-672. PubMed ID: 28276538
[TBL] [Abstract][Full Text] [Related]
7. VMAT2 Inhibitors: New Drugs for the Treatment of Tardive Dyskinesia.
Kim AP; Baker DE; Levien TL
Consult Pharm; 2018 Apr; 33(4):201-209. PubMed ID: 29609698
[TBL] [Abstract][Full Text] [Related]
8. Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.
Caroff SN; Aggarwal S; Yonan C
J Comp Eff Res; 2018 Feb; 7(2):135-148. PubMed ID: 28965423
[TBL] [Abstract][Full Text] [Related]
9. Valbenazine (Ingrezza) for tardive dyskinesia.
Med Lett Drugs Ther; 2017 May; 59(1521):83-84. PubMed ID: 28520698
[No Abstract] [Full Text] [Related]
10. Valbenazine for Tardive Dyskinesia.
Freudenreich O; Remington G
Clin Schizophr Relat Psychoses; 2017; 11(2):113-119. PubMed ID: 28742396
[TBL] [Abstract][Full Text] [Related]
11. The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study.
Factor SA; Remington G; Comella CL; Correll CU; Burke J; Jimenez R; Liang GS; O'Brien CF
J Clin Psychiatry; 2017; 78(9):1344-1350. PubMed ID: 29141124
[TBL] [Abstract][Full Text] [Related]
12. Valbenazine for the treatment of tardive dyskinesia.
Seeberger LC; Hauser RA
Expert Opin Pharmacother; 2017 Aug; 18(12):1279-1287. PubMed ID: 28699794
[TBL] [Abstract][Full Text] [Related]
13. Valbenazine in the treatment of tardive dyskinesia.
Witek N; Comella C
Neurodegener Dis Manag; 2019 Apr; 9(2):73-81. PubMed ID: 30724115
[TBL] [Abstract][Full Text] [Related]
14. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
Hauser RA; Factor SA; Marder SR; Knesevich MA; Ramirez PM; Jimenez R; Burke J; Liang GS; O'Brien CF
Am J Psychiatry; 2017 May; 174(5):476-484. PubMed ID: 28320223
[TBL] [Abstract][Full Text] [Related]
15. Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective.
Citrome L
Expert Rev Neurother; 2018 Apr; 18(4):323-332. PubMed ID: 29557243
[TBL] [Abstract][Full Text] [Related]
16. Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia.
Khorassani F; Luther K; Talreja O
Am J Health Syst Pharm; 2020 Jan; 77(3):167-174. PubMed ID: 31974564
[TBL] [Abstract][Full Text] [Related]
17. Valbenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2017 Jul; 71(7):. PubMed ID: 28497864
[TBL] [Abstract][Full Text] [Related]
18. Valbenazine granted breakthrough drug status for treating tardive dyskinesia.
Müller T
Expert Opin Investig Drugs; 2015 Jun; 24(6):737-42. PubMed ID: 25809133
[TBL] [Abstract][Full Text] [Related]
19. Valbenazine-induced parkinsonism.
Akbar U; Kim DS; Friedman JH
Parkinsonism Relat Disord; 2020 Jan; 70():13-14. PubMed ID: 31785443
[No Abstract] [Full Text] [Related]
20. Medication Options and Clinical Strategies for Treating Tardive Dyskinesia.
Citrome LL
J Clin Psychiatry; 2020 Jan; 81(2):. PubMed ID: 31995679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
